Disease strategy
Company wanted to prioritize Mood disorders to determine the level of investment in a Mood Disorders Franchise and to prioritize asset investment. Led a large, cross-functional team to conduct analytics and drive insight generation through workshops, leading to a fully endorsed strategic plan and accompanying funding.

Product launch
Led the global launch for a pharmaceutical company. Championed integration of key promotable endpoints into Phase III trial, and ensured Regulatory and Reimbursement success. Led creation of positioning, messaging and promotional materials. Created and implemented global training program. Created scorecard for monitoring this $2B+ product global launch.

Early product strategy development
Have partnered with pharmaceutical companies on over 100 early product strategies. Developed market, competitor and disease overviews. Led discussions with clinical team to define patient flow, buying process and key areas of unmet need where leverage points existed. As a result, have developed asset profiles that are competitive enough to be approved and successfully reimbursed.

Integrative Solutions approach
Company wanted to define a suite of wrap-around services ‘beyond the pill’. Leveraged patient segmentation approaches and gap analysis to define key unmet patient and caregiver needs. Led a cross-functional team to define suites of services that could be tailored by target segment. Developed an approach for business model assessment that included key opinion leader feedback, forecast model sensitivity analysis, and multi-attribute decision analysis.

US company launch
Led the establishment of a US company for a European Caregiver Intervention. Led Business Development and Advocacy Development to ensure a successful US business launch.

Advocacy Strategy
Company wanted to better understand the Advocacy and Policy landscape for a disease area. Led Marketing Research project with Advocacy groups, Professional Associations, key government organizations, and Policy-makers to define a long-term Advocacy strategy for company implementation. Provided a prioritized list of organizations and projects, as well as key messages that would resonate for each group.


"Terry Frangiosa possesses all the critical skill sets needed by next-generation, Pharmaceutical marketing. She has end-to-end command of the development lifecycle, is the rare marketer with deep understanding of the science as well as patient-centered treatment needs, appreciates the relevance of global policy, regulatory and economic dynamics and can effectively build all of this into a strategic, highly executable and global plan."

Magali Haas, Founder and CEO, Orion Bionetworks

"Terry’s expertise in new product marketing is absolutely top shelf. Best practices and state of the art are second nature. And her history of wins is pretty darned impressive. But it’s the combination of her high energy, great likeability and delight in whittling down complex data to its most essential ‘haiku’ that creates the differentiated value that impresses us."

Joseph Palumbo, Vice President and Head, Clinical Research, Mitsubishi Tanabe Pharma Development Corp.

"Terry runs her practice with a terrific combination of creativity, industry knowledge and structure. She has an ability to navigate and bring together ideas and points of view of a diversity of roles in the industry."

Margaret Theeuwes, Vice President Marketing, Ariosa Diagnostics